期刊文献+

含微生态制剂的四联疗法治疗初治失败的幽门螺杆菌感染31例 被引量:4

Effect of Quadruple Therapy Containing Microecologics on Helicobacter Pylori Infection after First Treatment Failure in 31 Cases
下载PDF
导出
摘要 目的观察含微生态制剂的四联疗法治疗初治失败的幽门螺杆菌感染的疗效和不良反应。方法将62例幽门螺杆菌根除失败的患者随机均分为两组,A组予雷贝拉唑+呋喃唑酮+阿莫西林+胶体果胶铋,B组予雷贝拉唑+呋喃唑酮+阿莫西林+微生态制剂,疗程均为7 d,治疗结束4周后复查14C-尿素呼气试验,判断是否根除幽门螺杆菌。结果 A组和B组幽门螺杆菌根除率分别为79.31%和83.33%(P>0.05);B组胃肠道不良反应少于A组(P<0.05)。结论含微生态制剂的四联疗法能有效根除初治失败的幽门螺杆菌感染,且能够显著降低治疗过程中的胃肠道不良反应。 Objective To observe the effects and adverse reactions of quadruple therapy with microecologics supplementation on Helicobacter pylori(HP) infection after first treatment failure.Methods Sixty-two cases of HP eradication failure were divided into two groups randomly,group A treated with rabeprazole+furazolidone+amoxillin+colloidal bismuth pectin and group B with rabeprazole+furazolidone+amoxicillin+microecologics,the treatment course was 7 d in both groups.The eradication of HP was redetermined by the 14C-urea breath test in 4 weeks after treatment.Results The eradication rate was 79.31% in group A and 83.33% in group B respectively(P0.05).The gastrointestinal adverse reactions in group B were fewer than those in group A(P0.05).Conclusion The quadruple therapy containing microecologics is effective in HP infection eradication after first treatment failure,furthermore,which may obviously reduce the adverse reactions in the treatment course.
出处 《中国药业》 CAS 2011年第9期58-59,共2页 China Pharmaceuticals
基金 浙江省自然科学基金项目 项目编号:Y2080675
关键词 微生态制剂 幽门螺杆菌 四联疗法 microecologics Helicobacter pylori quadruple therapy
  • 相关文献

参考文献13

  • 1Lai CH, Kuo CH, Chen PY, et al. Association of antibiotic resistance and higher internalization activity in resistant Helicobacter pylori isolates [ J ]. J Antimicrob Chemother, 2006, 57 (3) : 466 - 471.
  • 2Hooton C, Dempsey C, Keohane J, et al. Helicobacter pylori: prevalence of anti-microbial resistance in clinical isolates[J]. Br J Biomed Sci, 2006,63(3): 113 - 116.
  • 3Aleur N, Engel P, Carbajal N, et al. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract [J]. Appl Environ Microbiol, 2004, 70(2): 1 176 - 1 181.
  • 4Gessner BD, Bruce MG, Parkinson AJ, et al. A randomized trial of triple therapy for pediatric Helicobacter pylori infection and risk factors for treatment failure in a population with a high prevalence of infection [J]. Clin Infect Dis, 2005, 41 (9) : 1 261 - 1 268.
  • 5The European Helicobaeter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection[J]. The Maastricht Consensus Report Gut, 1997, 41 (1) : 8 - 13.
  • 6Graham DY,Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections[J]. Nat Clin Pract Gastroenterol Hepatol, 2008,5(6) :321 -331.
  • 7胡伏莲,胡品津,刘文忠,王继德,吕农华,萧树东,张万岱,成虹,谢勇.第三次全国幽门螺杆菌感染若干问题共识报告[J].胃肠病学,2008,13(1):42-46. 被引量:387
  • 8Sgouras D, Maragkoudakis P, Petraki KM, et al. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota[J]. Appl Environ Microbiol, 2004,70 ( 1 ) : 518 - 526.
  • 9Rmuzzi A, Cremonini F, Ojetti V, et al. Effect of actobacillus GG supplementation on antibiotic ssociated gastrointestinal side effects during elicobacter pylori eradication therapy: a pilot study[J]. Igcstion, 2001, 63 (1):1 -7.
  • 10Heu BS, Wu J J, Lo CY, et al. hnpact of supplement with Lactobacillus- and Bifidobacterium- containing yogurt on triple therapy for Helicobacter pylori eradication [ J ]. Aliment Pharmacol Ther, 2002, 16 (9) : 1669-1675.

二级参考文献17

  • 1Saad RJ,Schoenfeld P,Kim HM.左氧氟沙星三联疗法治疗顽固性Hp感染优于铋剂四联疗法[J].中国处方药,2006,5(5):42-42. 被引量:40
  • 2中国慢性胃炎共识意见[J].胃肠病学,2006,11(11):674-684. 被引量:834
  • 3Hunt RH,Xiao SD,Megraud F,Leon-Barua R,Bazzoli F,Van der Merwe S,vaz Coelho LG,Fock KM,Fedail S,Cohen H,Malfertheiner P,Vakil N,Hamid S,Goh KL,Wong BC,Krabshuis JH,杜颖,丛衍群,戴宁.世界胃肠病学组织(WGO-OMGE)临床指南——发展中国家幽门螺杆菌感染[J].胃肠病学,2007,12(1):40-52. 被引量:85
  • 4Malfertheiner P,Megraud F,O'Morain C,Hungin AP,Jones R,Axon A,Graham DY,Tytgat G, European Helicobacter Pylori Study Group (EHPSG).Current concepts in the management of Helicobacter pylori infection --the Maastricht 2-2000 Consensus Report.Aliment Pharmacol Ther,2002,16:167~180.
  • 5Megraud F.Adjuvant therapy for Helicobacter pylori eradication:role of lansoprazole shown in vitro.J Clin Gastroenterol,1995,20 (Suppl 1):S24~S27.
  • 6Fujiyama K,Fujioka T,Kodama R,Nasu M.Effect of E3810,a novel proton pump inhibitor against Helicobacter pylori.Am J Gastroenterol,1994,89:1371.
  • 7Hirai M,Azuma T,Ito S,Kato T,Kohli Y.A proton pump inhibitor,E3810,has antibacterial activity through binding to Helicobacter pylori.J Gastroenterol,1995,30:461~464.
  • 8Miwa H,Ohkura R,Murai T,Sato K,Nagahara A,Hirai S,Watanabe S,Sato N.Impact of rabeprazole,a new proton pump inhibitor,in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole.Aliment Pharmacol Ther,1999,13:741~746.
  • 9Buzas GM,Jozan J.Eradication of Helicobacter pylori infection in Europe:a meta-analysis based on congress abstracts,1997-2002.Orv Hetil,2004,145:2035~2041.
  • 10Goodwin CS,Marshall BJ,Blincow ED,Wilson DH,Blackbourn S,Phillips M.Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate:clinical and in vitro studies.J Clin Pathol,1988,41:207~210.

共引文献397

同被引文献44

  • 1成虹,胡伏莲.北京地区幽门螺杆菌耐药情况及其变化趋势[J].中华医学杂志,2005,85(39):2754-2757. 被引量:176
  • 2牟方宏,胡伏莲,杨桂彬,成虹.质子泵抑制剂四联疗法作为幽门螺杆菌根除治疗一线方案的临床研究[J].胃肠病学,2007,12(9):531-534. 被引量:71
  • 3Kengo T, Kazuhiro W, Akifumi T, et al. Evaluation of 13C-urea breath test to confirm eradication of Helicobacter pylori. Nippon ShokakibyoGakkai Zasshi ,2005,102 ( 2 ) : 176-182.
  • 4Hooton C, Dempsey C, Keohane J, et al. Helicobacter pylori: prevalence of antimicrobial resistance in clinical isolates. Br J Biomed Sci,2006,63 (3) : 113-116.
  • 5Schwab M, Schaeffeler E, Klotz U, et al. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther, 2004,76 ( 3 ) : 201-209.
  • 6Suttona, Lee. Helicobacter pylori vaccines the current status. Aliment Pharmacol Ther, 2000,14 : 1107-1118.
  • 7邱志洁,伊春锦,王玲玉.柴胡舒肝散治疗幽门螺杆菌阳性痞满证伴抑郁症的临床研究.中国现代医院杂志,2012,14(2):10-13.
  • 8谭小洪,魏金文,王晓燕,等.荆花胃康丸联合三联疗法治疗初冶失败幽门螺杆菌患者疗效评价[J].中国保健营养(中旬刊),2012.(z1):335—336.
  • 9Malfertheiner P,Megraud F,O'Morain CA. Management of Helicobacter pylori infection- -the Maastricht IV/Florence Consensus Report[J].{H}GUT,2012,(05):646-664.
  • 10Georgopoulos SD,Papastergiou V,Karatapanis S. Current options for the treatment of Helicobacter pylori[J].{H}EXPERT OPINION ON PHARMACOTHERAPY,2013,(02):211-223.

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部